Daily Baricitinib Treatment Preserves β-Cell Function in Type 1 Diabetes

THURSDAY, Dec. 7, 2023 -- Daily baricitinib treatment over 48 weeks preservesβ-cell function in patients with type 1 diabetes diagnosed recently, according to a study published in the Dec. 7 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news